8月8日，超研股份今日收盘27.28元，下跌2.57%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到73.83倍，总市值116.85亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入9843.24万元，同比28.69%；净利润3932.20万 元，同比47.70%，销售毛利率73.83%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13超研股份73.8380.279.03116.85亿行业平均 55.7051.864.84117.31亿行业中值39.0838.492.8857.46亿1九安医疗11.1411.270.88188.05亿2英科医疗 15.5716.791.39246.03亿3山东药玻16.0616.111.85151.90亿4振德医疗16.3115.371.0459.21亿5新华医疗 16.4415.241.34105.38亿6奥美医疗17.0016.661.7561.43亿7九强生物17.7016.462.1787.65亿8维力医疗 18.1019.342.2842.44亿9奥泰生物18.4319.441.4958.79亿10康德莱18.7118.721. ...

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有35家上市医疗设备公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到54%；50岁以上的CFO占比 为35%；40岁及以下CFO群体占比为11%。其中，目前仍任职的最年轻的上市公司CFO年龄30岁，为博 迅生物的金曼；最年长上市公司CFO年龄65岁，为超研股份的陈小波。 从薪酬分布看，A股医疗设备公司CFO年薪平均值为106.52万元。经统计，处于50万以下、50万-100 万、100万-200万、200万以上各区间的人数占比分别为31%、43%、20%、6%。 其中，年薪排行前三的CFO分别为迈瑞医疗的赵云、鱼跃医疗的刘丽华、万东医疗的井晓权，三人年 ...

Group 1 - The core viewpoint of the news is that Chao Yan Co., Ltd. (301602) has shown positive financial performance and stock market activity as of August 1, 2025, with a closing price of 27.52 yuan, reflecting a 2.88% increase [1] - The company reported total operating revenue of 98.43 million yuan for Q1 2025, representing a year-on-year growth of 28.69% [1] - The net profit attributable to shareholders reached 39.32 million yuan, with a year-on-year increase of 47.70%, and the non-recurring net profit was 36.96 million yuan, up 58.78% year-on-year [1] Group 2 - Chao Yan Co., Ltd. has a current liquidity ratio of 12.605 and a quick ratio of 11.524, indicating strong short-term financial health [1] - The company's debt-to-asset ratio stands at 8.39%, suggesting a low level of financial leverage [1] - The company has made investments in 12 enterprises and has participated in 703 bidding projects, showcasing its active engagement in the market [2]

汕头市超声仪器研究所股份有限公司的主营业务是医学影像设备、工业无损检测设备的研发、生产和销 售。公司的主要产品是工业超声、医用超声、X射线、配附件。经过多年积累，公司已拥有较高的市场 知名度和稳定的客户基础，工业超声无损检测产品被评为广东省名牌产品；2022年，公司凭借"复杂超 大构件高精密无损检测新技术及其重大应用"项目获得国家工业和信息化部颁发的国防技术发明奖二等 奖。 最新一期业绩显示，2025年一季报，公司实现营业收入9843.24万元，同比28.69%；净利润3932.20万 元，同比47.70%，销售毛利率73.83%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13超研股份72.3978.718.86114.58亿行业平均 54.8949.974.71114.46亿行业中值37.0636.862.6754.89亿1九安医疗10.9311.060.86184.50亿2英科医疗 14.2315.351.27224.88亿3新华医疗15.7214.571.28100.77亿4山东药玻15.9516.001.83150.91亿5奥美医疗 16.2315.911.6758.64亿6振德医疗16 ...

天眼查商业履历信息显示，汕头市超声仪器研究所股份有限公司，成立于1982年，位于汕头市，是一家 以从事其他制造业为主的企业。企业注册资本42832.9638万人民币，实缴资本36408.0192万人民币。公 司法定代表人为李德来。 超研股份最新一期业绩显示，截至2025一季报，公司营业总收入9843.24万元、同比增长28.69%，归属 净利润3932.20万元，同比增长47.70%，扣非净利润3695.85万元，同比增长58.78%，流动比率12.605、 速动比率11.524、资产负债率8.39%。 金融界消息 截至2025年7月31日收盘，超研股份（301602）报收于26.75元，下跌1.73%，换手率 10.56%，成交量6.16万手，成交金额1.66亿元。 通过天眼查大数据分析，汕头市超声仪器研究所股份有限公司共对外投资了12家企业，参与招投标项目 702次，知识产权方面有商标信息20条，专利信息238条，此外企业还拥有行政许可122个。 资金流向方面，今日主力资金净流出1251.31万元，占比成交额7.54%。其中，超大单净流出197.69万 元、占成交额1.19%，大单净流出1053.62万元 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Chao Yan Co., Ltd. in the medical device industry, noting its current stock price and market capitalization [1][2] - As of July 30, Chao Yan Co., Ltd. closed at 27.22 yuan, with a rolling PE ratio of 73.66, marking a new low in 17 days, and a total market value of 11.659 billion yuan [1] - The average PE ratio for the medical device industry is 55.15, with a median of 37.48, placing Chao Yan Co., Ltd. at the 94th position in the industry ranking [1][2] Group 2 - As of March 31, 2025, Chao Yan Co., Ltd. had 26,755 shareholders, a decrease of 23,411 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The main business of Chao Yan Co., Ltd. includes the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with key products being industrial ultrasound, medical ultrasound, X-ray, and accessories [1] - The company has established a strong market presence and customer base, with its industrial ultrasound non-destructive testing products recognized as a Guangdong Province brand product [1] - In 2022, Chao Yan Co., Ltd. received a second-class award for national defense technology invention from the Ministry of Industry and Information Technology for its project on new technology for high-precision non-destructive testing of complex large components [1] - For the first quarter of 2025, the company reported revenue of 98.43 million yuan, a year-on-year increase of 28.69%, and a net profit of 39.32 million yuan, up 47.70%, with a gross profit margin of 73.83% [1]

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., specializes in the research, production, and sales of medical imaging and industrial non-destructive testing equipment, benefiting from the depreciation of the RMB and the growing pet economy [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is a national key high-tech enterprise focusing on medical imaging and industrial non-destructive testing equipment [7]. - The company's main business revenue composition includes: medical ultrasound 50.32%, industrial ultrasound 19.04%, X-ray 16.30%, accessories 12.52%, and others 1.82% [7]. Financial Performance - For the period from January to March 2025, the company achieved operating revenue of 98.43 million yuan, representing a year-on-year growth of 28.69%. The net profit attributable to the parent company was 39.32 million yuan, with a year-on-year increase of 47.70% [8]. - As of March 31, 2025, the company had a total of 26,800 shareholders, a decrease of 46.67% from the previous period, with an average of 2,047 circulating shares per person, an increase of 87.50% [8]. Market Position and Trends - The company participated in the 97th WVC annual meeting from March 3 to 5, 2025, showcasing innovations in veterinary medical imaging for pets, horses, and livestock, and engaging with industry experts [2]. - The company’s overseas revenue accounted for 55.26% of total revenue, benefiting from the depreciation of the RMB [3]. Technical Analysis - The average trading cost of the stock is 26.58 yuan, with the current stock price near a support level of 26.85 yuan. If the price falls below this support level, it may trigger a downward trend [6].

Company Overview - Chao Yan Co., Ltd. closed at 27.17 yuan, up 1.95%, with a rolling PE ratio of 73.53, marking a new low in 14 days, and a total market value of 11.638 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 55.41 and a median of 37.94, placing Chao Yan at the 96th position in the industry ranking [1] - As of the first quarter of 2025, 118 institutions held shares in Chao Yan, with a total holding of 71,100 shares valued at 0.02 billion yuan [1] Business Operations - Chao Yan specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment [1] - The main products include industrial ultrasound, medical ultrasound, X-ray, and related accessories [1] - The company has established a strong market presence and stable customer base, with its industrial ultrasound non-destructive testing products recognized as a Guangdong Province brand [1] - In 2022, the company received a second-class National Defense Technology Invention Award from the Ministry of Industry and Information Technology for its project on "New Technology for High-Precision Non-Destructive Testing of Complex Large Components and Its Major Applications" [1] Financial Performance - In the first quarter of 2025, Chao Yan reported operating revenue of 98.4324 million yuan, a year-on-year increase of 28.69% [1] - The net profit for the same period was 39.3220 million yuan, reflecting a year-on-year growth of 47.70% [1] - The sales gross margin stood at 73.83% [1]

Group 1 - The company has completed its initial public offering (IPO) and the total share capital is now 428,329,638 shares, with 373,553,188 shares subject to trading restrictions, accounting for 87.21% of the total share capital [1][2] - A total of 3,577,474 shares, representing 0.84% of the total share capital, will be released from trading restrictions after a 6-month lock-up period starting from the IPO date [1][2] - The shareholders holding the restricted shares have complied with their commitments during the lock-up period, and there are no violations regarding the use of company funds or guarantees [2] Group 2 - The breakdown of shares before and after the release of trading restrictions shows that the number of restricted shares decreased from 373,553,188 to 369,975,714, while the number of unrestricted shares increased from 54,776,450 to 58,353,924 [4] - The total share capital remains unchanged at 428,329,638 shares [4] - The sponsor has confirmed that the application for the release of restricted shares complies with relevant regulations and the information disclosed is accurate and complete [5]

证券代码：301602 证券简称：超研股份 公告编号：2025-032 汕头市超声仪器研究所股份有限公司 关于首次公开发行网下配售限售股份上市流通提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 根据公司《首次公开发行股票并在创业板上市之上市公告书》： "网下发行部分采用比例限售方式，网下投资者应当承诺其获配股票 数量的 10%（向上取整计算）限售期限为自发行人首次公开发行并上 市之日起 6 个月。即每个配售对象获配的股票中，90%的股份无限售 期，自本次发行股票在深交所上市交易之日起即可流通；10%的股份 限售期为 6 个月，限售期自本次发行股票在深交所上市交易之日起开 始计算。" 1、本次上市流通的限售股份为汕头市超声仪器研究所股份有限公 司（以下简称"公司"）首次公开发行网下配售限售股份。 2、本次解除限售的股东户数为 5,911 户，解除限售股份数量为 3,577,474 股，占公司总股本比例为 0.84%，限售期为自公司首次公 开发行并上市之日起 6 个月，本次解除限售的股份可上市流通日为 2025 年 7 月 22 日(星期二 ...